Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jennifer Trujillo to Weight Loss

This is a "connection" page, showing publications Jennifer Trujillo has written about Weight Loss.

 
Connection Strength
 
 
 
0.475
 
  1. Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
    View in: PubMed
    Score: 0.148
  2. Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. Ann Pharmacother. 2018 12; 52(12):1224-1232.
    View in: PubMed
    Score: 0.110
  3. Nuffer WA, Trujillo JM. Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy. 2015 Oct; 35(10):926-34.
    View in: PubMed
    Score: 0.091
  4. Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014 Nov; 34(11):1174-86.
    View in: PubMed
    Score: 0.085
  5. Nuffer W, Trujillo JM, Megyeri J. A Comparison of New Pharmacological Agents for the Treatment of Obesity. Ann Pharmacother. 2016 May; 50(5):376-88.
    View in: PubMed
    Score: 0.023
  6. Anderson SL, Trujillo JM, McDermott M, Saseen JJ. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003). 2012 Jul-Aug; 52(4):466-71.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)